Sourcing Exosomes in Virginia
Licensed Virginia practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Virginia buyers need their own professional license and NPI; the nonresident wholesale distributor registration is the supplier’s obligation, not the purchaser’s.
Virginia’s most useful rule for a delegating practice is also its most explicit: before anything is prescribed, Virginia law spells out what a bona fide practitioner-patient relationship requires, including an appropriate examination. Build protocols around that section and most of the rest follows.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Virginia? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Virginia
ExaVeyra ships to licensed practices in all 50 states, Virginia included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Virginia professional license in good standing, verifiable through the Department of Health Professions License Lookup.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Virginia sales and use tax resale exemption certificate if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Virginia runs a two-track regime under the Drug Control Act. A firm distributing prescription drugs at wholesale inside the Commonwealth holds the wholesale distributor license under section 54.1-3435, while a firm located outside Virginia that ships prescription drugs in registers as a nonresident wholesale distributor under section 54.1-3435.01, renewing annually at the same fee as the in-state license. A nonresident registrant must hold a valid license in its home state, prove it, and produce records to the Board of Pharmacy within seven days of a request. The regime covers prescription drugs, and the registration sits with the distributor, not with the purchasing practice.
Va. Code 54.1-3435, 54.1-3435.01 (Drug Control Act) · Virginia Board of Pharmacy, Department of Health Professions
Virginia regenerative-medicine law
Virginia has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Virginia has no statute that authorizes, conditions, or requires disclosure for unapproved regenerative therapy, so federal law is the only layer that addresses it. What Virginia does have is the Christopher Reeve Stem Cell Research Fund, section 32.1-162.31 of the Code of Virginia, a permanent fund supporting medical and biomedical stem cell research at institutions of higher education, expressly excluding research on cells obtained from human embryos. A companion fund, the Florence Neal Cooper Smith Sickle Cell Research Endowment in section 32.1-162.31:1, works the same way. Both are research funding mechanisms, not practice authorizations, and neither permits or conditions any clinical service. Practice in this area is governed by the Boards of Medicine, Nursing, and Pharmacy under Title 54.1, alongside federal law.
How this applies to exosomes
Virginia has not enacted a stem cell authorization law like Florida, Texas, or Georgia, a disclosure law like California or Utah, or a documentation statute like Tennessee. The Christopher Reeve Stem Cell Research Fund is sometimes cited as though Virginia had legislated on stem cell therapy; it funds university research and says nothing about clinical practice. There is therefore no Virginia definition to read exosomes into or out of, and exosomes are acellular extracellular vesicles that no state statute here addresses. Exosome products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Virginia practice
Virginia offers two workable structures: a physician-led practice delegating conventionally, and an autonomous nurse practitioner practice once the three-year threshold is met, with a medical director still needed where a procedure falls outside NP scope or a payer requires one. The practical constant across both is section 54.1-3303: whoever prescribes must first have the bona fide practitioner-patient relationship, with an appropriate examination. All three boards sit within one agency, the Department of Health Professions, so license verification runs through a single lookup.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Virginia Board of Medicine may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. Prescribing requires the bona fide practitioner-patient relationship of section 54.1-3303. |
| NP / APRN | Nurse practitioners practice under a written or electronic practice agreement with a patient care team physician. Under section 54.1-2957, a nurse practitioner who has completed the equivalent of at least three years of full-time clinical experience, as determined by the Boards of Medicine and Nursing, may qualify for autonomous practice in the category of licensure without an agreement. |
| PA | Physician assistants practice under a practice agreement as part of a patient care team under section 54.1-2952, within the scope the agreement sets. Section 54.1-2952.01 adds an experience path: with an attestation of the equivalent of at least three years of full-time clinical experience in a specialty, a PA may practice in that specialty without a separate practice agreement, still consulting and referring as patient conditions require. |
| RN | Registered nurses perform delegated treatments within their scope and under a valid order from a provider with prescriptive authority, after that provider has established the bona fide practitioner-patient relationship. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Virginia codifies the good faith examination more explicitly than most states. Section 54.1-3303 requires a bona fide practitioner-patient relationship before prescribing: a medical or drug history, information about the benefits and risks of the drug, an appropriate examination performed physically or by instrumentation, and follow-up where the drug warrants it. Except in emergencies, the examination is conducted by the prescriber, a practitioner in the same group, or a consulting practitioner.
Ownership and clinic licensing
Virginia does not codify a corporate practice of medicine prohibition the way Texas, New York, or New Jersey do. Professional entities and management services arrangements are the usual structures, and physicians are commonly employed by health systems and clinic companies. Because the position rests on professional entity law and board regulation rather than a bright-line statute, published summaries disagree at the margins, so treat ownership structure as a question for Virginia counsel and the Department of Health Professions rather than one a guide should answer with a percentage.
Cold chain into Virginia
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Virginia order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Virginia Beach | Largest Virginia city, anchoring the Hampton Roads aesthetic market. | |
| Richmond | Capital market with dermatology and a growing med spa corridor. | |
| Arlington | Arlington | Northern Virginia market inside the Washington metro. |
| McLean | Fairfax | Affluent Fairfax County market with concierge and aesthetic practices. |
| Norfolk | Hampton Roads clinical hub served alongside Virginia Beach. | |
| Charlottesville | University market with academic medicine and a steady aesthetic segment. |
- Virginia orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- The lot-specific Certificate of Analysis is provided on request for every lot; the manufacturer’s handling instructions accompany each order, so store to the labeled conditions on arrival.
Wholesale exosome supply by city in Virginia
Each city page covers local receiving conditions, delivery disruptions and business license rules for Virginia practices in that area.
Practice types we supply in Virginia
Virginia licensing and verification
Virginia Board of Medicine
Licenses physicians and, with the Board of Nursing, jointly regulates nurse practitioners.
Virginia Board of Nursing
Virginia Board of Pharmacy
Licenses wholesale distributors and registers nonresident wholesale distributors.
Virginia Department of Health Professions
Hosts all three boards and the License Lookup used to verify practitioners.
Virginia sourcing questions
- Does Virginia have a stem cell law?
- Not a practice law. The Christopher Reeve Stem Cell Research Fund in section 32.1-162.31 of the Code of Virginia funds stem cell research at institutions of higher education, excluding embryonic stem cell work, and is regularly mistaken for a clinical statute. Virginia has no stem cell authorization law, disclosure law, or documentation statute, so exosome products there are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, in Virginia or anywhere else, and the FDA has issued a public safety notification saying exactly that. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- Can a Virginia nurse practitioner practice without a physician?
- After the threshold, yes. A nurse practitioner who has completed the equivalent of at least three years of full-time clinical experience, as determined by the Boards of Medicine and Nursing, may qualify under section 54.1-2957 for autonomous practice without a practice agreement. Before that, practice runs under a written or electronic agreement with a patient care team physician. A medical director is still needed where a procedure falls outside NP scope or a payer requires one.
- What does Virginia require before a delegated treatment?
- A bona fide practitioner-patient relationship under section 54.1-3303: a medical or drug history, information about benefits and risks, an appropriate examination performed physically or by instrumentation, and follow-up where warranted. Registered nurses administer only under a valid order issued after that relationship exists.
- Does my Virginia clinic need a wholesale distributor registration to buy exosomes?
- No. The nonresident wholesale distributor registration under section 54.1-3435.01 is held by the distributor shipping into Virginia, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to Virginia?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Va. Code 54.1-3435.01, registration of nonresident wholesale distributors (accessed 16 October 2026)
- Va. Code 54.1-3435, license to act as wholesale distributor (accessed 16 October 2026)
- Va. Code 54.1-2957, nurse practitioner licensure and autonomous practice (accessed 16 October 2026)
- Va. Code 54.1-3303, bona fide practitioner-patient relationship (accessed 16 October 2026)
- Va. Code 32.1-162.31, Christopher Reeve Stem Cell Research Fund (accessed 16 October 2026)
- Virginia Board of Pharmacy (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark reporting standard for extracellular vesicle studies, the basis for the characterization fields a Virginia practice should expect on an exosome Certificate of Analysis.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that in a state with no regenerative statute, supplier documentation against international standards is the quality layer that exists.
- Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.27066 PMID:25979354Narrative reviewsupports: The foundational review of what extracellular vesicles are, supporting this page’s distinction between acellular vesicles and the stem cells that Virginia’s research fund, and other states’ statutes, actually address.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.